Monitoring ovarian cancer using urine cyclic GMP. A two-centre study

G. A. Turner, S. Greggi, D. Guthrie, P. Benedetti Panici, R. D. Ellis, G. Scambia, S. Mancuso

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The usefulness of urine cyclic guanosine 3'-5'monophosphate GMP (cGMP) as a cancer marker in ovarian cancer has been studied in two independent centres using specimens from 81 women. Serial specimens from 60 patients were monitored up to 2 years after the start of chemotherapy. Urine cGMP levels were significantly higher in those patients with poorly differentiated tumours. Levels were not associated with the tumour stage, histological type or residual tumour remaining after surgery. Pretreatment levels were of no value for predicting response to therapy or patient survival. During therapy, however, levels did confirm clinical observations and if a level was elevated then there was a 80-90% chance that the patient was not responding to therapy. Using serial measurements, it was possible to predict the recurrence of tumour in 16/25 patients prior to any other clinical signs.

Original languageEnglish
Pages (from-to)421-427
Number of pages7
JournalEuropean Journal of Gynaecological Oncology
Volume11
Issue number6
Publication statusPublished - 1990

Fingerprint

Cyclic GMP
Guanosine Monophosphate
Ovarian Neoplasms
Urine
Neoplasms
Residual Neoplasm
Therapeutics
Recurrence
Drug Therapy
Survival

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Turner, G. A., Greggi, S., Guthrie, D., Benedetti Panici, P., Ellis, R. D., Scambia, G., & Mancuso, S. (1990). Monitoring ovarian cancer using urine cyclic GMP. A two-centre study. European Journal of Gynaecological Oncology, 11(6), 421-427.

Monitoring ovarian cancer using urine cyclic GMP. A two-centre study. / Turner, G. A.; Greggi, S.; Guthrie, D.; Benedetti Panici, P.; Ellis, R. D.; Scambia, G.; Mancuso, S.

In: European Journal of Gynaecological Oncology, Vol. 11, No. 6, 1990, p. 421-427.

Research output: Contribution to journalArticle

Turner, GA, Greggi, S, Guthrie, D, Benedetti Panici, P, Ellis, RD, Scambia, G & Mancuso, S 1990, 'Monitoring ovarian cancer using urine cyclic GMP. A two-centre study', European Journal of Gynaecological Oncology, vol. 11, no. 6, pp. 421-427.
Turner GA, Greggi S, Guthrie D, Benedetti Panici P, Ellis RD, Scambia G et al. Monitoring ovarian cancer using urine cyclic GMP. A two-centre study. European Journal of Gynaecological Oncology. 1990;11(6):421-427.
Turner, G. A. ; Greggi, S. ; Guthrie, D. ; Benedetti Panici, P. ; Ellis, R. D. ; Scambia, G. ; Mancuso, S. / Monitoring ovarian cancer using urine cyclic GMP. A two-centre study. In: European Journal of Gynaecological Oncology. 1990 ; Vol. 11, No. 6. pp. 421-427.
@article{8cfcd03ae0c742bd8b726a2283fdf723,
title = "Monitoring ovarian cancer using urine cyclic GMP. A two-centre study",
abstract = "The usefulness of urine cyclic guanosine 3'-5'monophosphate GMP (cGMP) as a cancer marker in ovarian cancer has been studied in two independent centres using specimens from 81 women. Serial specimens from 60 patients were monitored up to 2 years after the start of chemotherapy. Urine cGMP levels were significantly higher in those patients with poorly differentiated tumours. Levels were not associated with the tumour stage, histological type or residual tumour remaining after surgery. Pretreatment levels were of no value for predicting response to therapy or patient survival. During therapy, however, levels did confirm clinical observations and if a level was elevated then there was a 80-90{\%} chance that the patient was not responding to therapy. Using serial measurements, it was possible to predict the recurrence of tumour in 16/25 patients prior to any other clinical signs.",
author = "Turner, {G. A.} and S. Greggi and D. Guthrie and {Benedetti Panici}, P. and Ellis, {R. D.} and G. Scambia and S. Mancuso",
year = "1990",
language = "English",
volume = "11",
pages = "421--427",
journal = "European Journal of Gynaecological Oncology",
issn = "0392-2936",
publisher = "S.O.G. CANADA Inc.",
number = "6",

}

TY - JOUR

T1 - Monitoring ovarian cancer using urine cyclic GMP. A two-centre study

AU - Turner, G. A.

AU - Greggi, S.

AU - Guthrie, D.

AU - Benedetti Panici, P.

AU - Ellis, R. D.

AU - Scambia, G.

AU - Mancuso, S.

PY - 1990

Y1 - 1990

N2 - The usefulness of urine cyclic guanosine 3'-5'monophosphate GMP (cGMP) as a cancer marker in ovarian cancer has been studied in two independent centres using specimens from 81 women. Serial specimens from 60 patients were monitored up to 2 years after the start of chemotherapy. Urine cGMP levels were significantly higher in those patients with poorly differentiated tumours. Levels were not associated with the tumour stage, histological type or residual tumour remaining after surgery. Pretreatment levels were of no value for predicting response to therapy or patient survival. During therapy, however, levels did confirm clinical observations and if a level was elevated then there was a 80-90% chance that the patient was not responding to therapy. Using serial measurements, it was possible to predict the recurrence of tumour in 16/25 patients prior to any other clinical signs.

AB - The usefulness of urine cyclic guanosine 3'-5'monophosphate GMP (cGMP) as a cancer marker in ovarian cancer has been studied in two independent centres using specimens from 81 women. Serial specimens from 60 patients were monitored up to 2 years after the start of chemotherapy. Urine cGMP levels were significantly higher in those patients with poorly differentiated tumours. Levels were not associated with the tumour stage, histological type or residual tumour remaining after surgery. Pretreatment levels were of no value for predicting response to therapy or patient survival. During therapy, however, levels did confirm clinical observations and if a level was elevated then there was a 80-90% chance that the patient was not responding to therapy. Using serial measurements, it was possible to predict the recurrence of tumour in 16/25 patients prior to any other clinical signs.

UR - http://www.scopus.com/inward/record.url?scp=0025634050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025634050&partnerID=8YFLogxK

M3 - Article

C2 - 1964900

AN - SCOPUS:0025634050

VL - 11

SP - 421

EP - 427

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

SN - 0392-2936

IS - 6

ER -